View clinical trials related to Opioid-Induced Bowel Dysfunction.
Filter by:Tramadol is a weak opioid and widely used to treat moderate to severe pain. Stronger opioids are known to inhibit gastrointestinal motility and secretion, however the effects of tramadol on gastrointestinal function remains less understood. The aim of this study was to determine to what degree tramadol causes opioid-induced bowel dysfunction by using an objective design to explore gastrointestinal transit, motility pattern, secretion, and colonic volume, in a group of healthy male volunteers.
The primary purpose of the study is to evaluate the efficacy and safety of lubiprostone administration in subjects with Opioid-induced Bowel Dysfunction.
Study consists of 6 treatment cohorts of 12 subjects with chronic pain, opioid-induced bowel dysfunction, and opioid physical dependence. Total duration of treatment for each subject will be up to 28 days. Each subject will receive a single dose of study drug, administered orally in the morning of Day 15 under fasted conditions. Cohort 1: 0.1 mg of S-297995 or placebo. Cohort 2: 0.3 mg of S-297995 or placebo. Cohort 3: 1 mg of S-297995 or placebo. Cohort 4: 3 mg of S-297995 or placebo. Cohort 5: 0.03 mg of S-297995 or placebo. Cohort 6: 0.01 mg of S-297995 or placebo. The primary objective of the study is to evaluate the safety of single doses of oral S-297995 in subjects physically dependent on opioids
The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.
The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with opioid-induced bowel dysfunction (OBD).
The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with Opioid-induced Bowel Dysfunction.